Pre-revenue nuclear startup Oklo has seen its stock price plummet over 40% in 2026 as investors question its commercial viability. Despite high-profile backing, the company struggles with regulatory hurdles and a valuation that dwarfs its competitors.
- Stock price has dropped over 40% in 2026
- Valuation of $8 billion exceeds NRC-approved competitor NuScale Power
- Aurora micro-reactors remain untested at commercial scale
- Company holds $788 million in cash as of year-end 2025
- Regulatory licensing remains the primary barrier to revenue generation
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.